» Articles » PMID: 18097637

Impact of Vessel Size on Distal Embolization, Myocardial Perfusion and Clinical Outcome in Patients Undergoing Primary Angioplasty for ST-segment Elevation Myocardial Infarction

Overview
Date 2007 Dec 22
PMID 18097637
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mounting interest has emerged on the role of distal embolization as a major explanation of poor myocardial perfusion among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary angioplasty. The aim of the current study was to evaluate the relationship between vessel size, distal embolization, myocardial perfusion and clinical outcome in patients with STEMI treated by primary angioplasty.

Methods: Our population is represented by 1969 patients with STEMI undergoing primary stenting from 1997 to 2002. All clinical, angiographic, and follow-up data were prospectively collected.

Results: Vessel size was linearly associated with gender, diabetes, anterior infarction location, shorter time-delay, the rate of stenting and glycoprotein IIb-IIIa inhibitors. Small vessel size was associated with poor perfusion, despite lower rates of distal embolization. These data were confirmed after correction for confounding factors. The higher risk profile and poor myocardial perfusion contribute to explain the worse outcome observed in patients with smaller vessel size.

Conclusions: This study shows that in patients undergoing primary angioplasty for STEMI, small vessel size is associated with poor myocardial perfusion, despite less distal embolization, that contributes to explain the worse outcome observed among patients with small infarct related arteries.

Citing Articles

Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction.

De Luca G, Verburg A, Vant Hof A, Berg J, Kereiakes D, Coller B Biomedicines. 2024; 12(9).

PMID: 39335537 PMC: 11428685. DOI: 10.3390/biomedicines12092023.


Associations of Culprit Vessel Size and Plaque Characteristics in Patients with ST-Segment Elevation Myocardial Infarction.

Li J, Chen R, Zhou J, Wang Y, Zhao X, Liu C Rev Cardiovasc Med. 2024; 24(7):186.

PMID: 39077009 PMC: 11266472. DOI: 10.31083/j.rcm2407186.


Culprit Lesion Vessel Size and Risk of Reperfusion Injury in ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging Study.

Lechner I, Reindl M, Tiller C, Holzknecht M, Oberhollenzer F, Mayr A J Am Heart Assoc. 2024; 13(3):e033102.

PMID: 38293938 PMC: 11056128. DOI: 10.1161/JAHA.123.033102.


Sex-Specific Treatment Effects After Primary Percutaneous Intervention: A Study on Coronary Blood Flow and Delay to Hospital Presentation.

Cenko E, van der Schaar M, Yoon J, Kedev S, Valvukis M, Vasiljevic Z J Am Heart Assoc. 2019; 8(4):e011190.

PMID: 30764687 PMC: 6405653. DOI: 10.1161/JAHA.118.011190.


The effectiveness and safety of the RESTORE drug-eluting balloon versus a drug-eluting stent for small coronary vessel disease: study protocol for a multi-center, randomized, controlled trial.

Tang Y, Qiao S, Su X, Chen Y, Jin Z, Chen H J Geriatr Cardiol. 2018; 15(7):469-475.

PMID: 30364848 PMC: 6198267. DOI: 10.11909/j.issn.1671-5411.2018.07.006.


References
1.
Vijayalakshmi K, Kunadian B, Whittaker V, Williams D, Wright R, Sutton A . The impact of chronically diseased coronary arteries and stenting on the corrected TIMI frame count in elective coronary angiography and percutaneous coronary intervention procedures. Catheter Cardiovasc Interv. 2007; 70(5):691-700. DOI: 10.1002/ccd.21215. View

2.
De Luca G, Suryapranata H, Stone G, Antoniucci D, Tcheng J, Neumann F . Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005; 293(14):1759-65. DOI: 10.1001/jama.293.14.1759. View

3.
Stone G, Webb J, Cox D, Brodie B, Qureshi M, Kalynych A . Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005; 293(9):1063-72. DOI: 10.1001/jama.293.9.1063. View

4.
Umeda H, Iwase M, Izawa H, Katoh T, Gochi T, Toyama J . Is it possible to predict which patients need distal protection during primary angioplasty?. Int J Cardiol. 2007; 127(2):179-85. DOI: 10.1016/j.ijcard.2007.04.076. View

5.
Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T . Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999; 33(3):654-60. DOI: 10.1016/s0735-1097(98)00604-4. View